Exhaled nitric oxide continues to reflect airway hyperresponsiveness and disease activity in inhaled corticosteroid-treated adult asthmatic patients

Respirology

Volumn 8, Issue 4, 2003, Pages 479-486

  Reid, David W ^a,b   Johns, David P ^b   Feltis, Bryce ^b   Ward, Chris ^a   Walters, E Haydn ^b  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Airway hyperresponsiveness; Asthma; Corticosteroids; Nitric oxide

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; METHACHOLINE; NITRIC OXIDE; SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPUTUM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BIOLOGICAL MARKERS; BRONCHIAL HYPERREACTIVITY; CROSS-SECTIONAL STUDIES; DRUG MONITORING; EOSINOPHILS; FEMALE; HUMANS; LINEAR MODELS; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITRIC OXIDE; SEVERITY OF ILLNESS INDEX; SPUTUM; STATISTICS, NONPARAMETRIC;

EID: 0348148819     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1843.2003.00495.x     Document Type: Article

References (32)

1. Bradley BL, Azzawi M, Jacobson M et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 1991; 88: 661-74.
2. Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am. Rev. Respir. Dis. 1990; 141: S70-6.
3. Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur. Respir. J. 2003; 21: 433-8.
4. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343: 133-5.
5. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53: 91-5.
6. Berlyne GS, Parameswaran K, Kamada D, Efthimiadis A, Hargreave FE. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J. Allergy Clin. Immunol. 2000; 106: 638-44.
7. Tsujino I, Nishimura M, Kamachi A et al. Exhaled nitric oxide-is it really a good marker of airway inflammation in bronchial asthma? Respiration 2000; 67: 645-51.
8. Lim S, Jatakanon A, Meah S, Oates T, Chung KF, Barnes PJ. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax 2000; 55: 184-8.
9. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am. Rev. Respir. Dis. 1987; 136: 225-44.
10. Silkoff PE, McClean PA, Slutsky AS et al. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am. J. Respir. Crit. Care Med. 1997; 155: 260-7.
11. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am. Rev. Respir. Dis. 1993; 147: 1126-31.
12. Kips JC, Fahy JV, Hargreave FE, Ind PW, in't Veen JC. Methods for sputum induction and analysis of induced sputum: a method for assessing airway inflammation in asthma. Eur. Respir. J. Suppl. 1998; 26: 9S-12S.
13. Beach JR, Young CL, Avery AJ et al. Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response. Thorax 1993; 48: 239-43.
14. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999; 54: 403-8.
15. Saleh D, Ernst P, Lim S, Barnes PJ, Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEB J. 1998; 12: 929-37.
16. Lim S, Jatakanon A, John M et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 22-30.
17. Leuppi JD, Salome CM, Jenkins CR et al. Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma. Eur. Respir. J. 2001; 18: 444-50.
18. Barnes PJ, Belvisi MG. Nitric oxide and lung disease. Thorax 1993; 48: 1034-43.
19. Barnes PJ. Nitric oxide and airways. Eur. Respir. J. 1993; 6: 163-5.
20. Redington AE, Meng QH, Springall DR et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment. Thorax 2001; 56: 351-7.
21. Gao PS, Kawada H, Kasamatsu T et al. Variants of NOS1, NOS2, and NOS3 genes in asthmatics. Biochem. Biophys. Res. Commun. 2000; 267: 761-3.
22. De Sanctis GT, MacLean JA, Hamada K et al. Contribution of nitric oxide synthases 1, 2, and 3 to airway hyperresponsiveness and inflammation in a murine model of asthma. J. Exp. Med. 1999; 189: 1621-30.
23. De Sanctis GT, Mehta S, Kobzik L et al. Contribution of type I NOS to expired gas NO and bronchial responsiveness in mice. Am. J. Physiol. 1997; 273: L883-8.
24. Howarth PH, Redington AE, Springall DR et al. Epithelially derived endothelin and nitric oxide in asthma. Int. Arch. Allergy Immunol. 1995; 107: 228-30.
25. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-8.
26. Mathur M, Herrmann K, Li X et al. TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 580-7.
27. Matsumoto K, Saito H. The role of eosinophils in asthma: Sarastro or the Queen of the Night? Int. Arch. Allergy Immunol. 2001; 125: 290-6.
28. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to longterm treatment. The AMPUL Study Group. Am. J. Respir. Crit. Care Med. 1999; 159: 1043-51.
29. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999; 54: 289-95
30. Montefort S, Roberts JA, Beasley R, Holgate ST, Roche WR. The site of disruption of the bronchial epithelium in asthmatic and non-asthmatic subjects. Thorax 1992; 47: 499-503.
31. Nijkamp FP, Folkerts G. Nitric oxide and bronchial reactivity. Clin. Exp. Allergy 1994; 24: 905-14.
32. Pin I, Gibson PG, Kolendowicz R et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-9.